GlassScriptPhysician profile
Emma Atherton-Staples
NPI 1780063339
$4,790.82
in general payments reported to CMS, 2019-2025
32 companies · $1,213 in 2025
The $1,213 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $209 · 2021: $142 · 2022: $374 · 2023: $1,097 · 2024: $1,360 · 2025: $1,213.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,626 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,625.93 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $831.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $705.69 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $641.04 | 2021-2025 | Vraylar, Qulipta |
| Pfizer INC. | $481.02 | 2019-2025 | |
| Noven Therapeutics, LLC | $300.63 | 2023-2025 | Xelstrym |
| Glaxosmithkline, LLC. | $290.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $197.40 | 2019-2025 | Farxiga, Breztri |
| Amgen INC. | $166.72 | 2019-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $144.62 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $132.93 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.55 | 2019-2025 | Jardiance |
| Astellas Pharma US INC | $102.95 | 2023-2024 | Veozah |
| Dynavax Technologies Corporation | $81.00 | 2023-2025 | Heplisav-B |
| Daiichi Sankyo INC. | $67.26 | 2020-2023 | Injectafer |
| Idorsia Pharmaceuticals US INC | $64.80 | 2022-2023 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $53.49 | 2019-2020 | |
| Inspire Medical Systems, INC. | $52.52 | 2025 | Inspire |
| Abbott Laboratories | $49.87 | 2022-2023 | Freestyle Libre 3 |
| Neos Therapeutics, LP | $34.48 | 2024 | Adzenys Xr-Odt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.95 | 2024 | Xifaxan |
| Esperion Therapeutics, INC. | $29.45 | 2022-2025 | Nexletol |
| Corium, LLC | $29.27 | 2024 | Azstarys |
| Almatica Pharma LLC | $24.31 | 2024 | Loreev Xr |
| Tris Pharma INC | $21.97 | 2023 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $20.26 | 2022 | |
| Nevro Corp. | $19.35 | 2024 | Senza |
| Sanofi Pasteur INC. | $17.36 | 2023 | |
| Merck Sharp & Dohme LLC | $17.13 | 2019 | |
| Halozyme INC | $17.02 | 2023 | |
| Genentech USA, INC. | $14.21 | 2020 | |
| Lantheus Medical Imaging, INC. | $13.86 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.16 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Atherton-Staples listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.